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ever, patients with BMI >25 are at increased risk of recurrent AMI. This finding suggests 
the need to aggressively intervene in obese and overweight patients following the index 
AM1 to reduce the long-term risk of recurrent events. 
(15.6) yrs, 54% female, and 37% AA. AA had higher mean distrust scores than C 
patients (2.6k1.7 vs. 1.5t1.5, p<O.OOOl). AA more often reported that doctors would less 
fully explain research to them (25% vs. 13%. pcO.OOl), use them as guinea pigs without 
consent (73% vs. 50%. p<O.OOl), prescribe medication as a way of experimenting on 
people without their knowledge (59% vs. 26% pcO.OOl), and ask them to join research 
even if It could harm them (26% vs. 16%, p=O.O03). AA also more often believed they 
could less freely ask their doctor questions (8% vs. 2%, p=O.OOl) and were previously 
expenmented on without their consent (55% vs. 45%, p<O.OOi). Fewer AA than C were 
WTP (29% vs. 38%, respectively, p=O.O3); however, this difference was no longer signif- 
icant after controlling for distrust and sociodemographics (OR=0.82, 95% Cl 0.55-1.22). 
Every one-point increase in distrust score predicted a 27% lower odds of WTP, OR=0.73 
(0.65-0.83, p<O.OOl). 
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1193-58 What is the Meaning of High-Risk? A Prospective 
Comparison of Three Risk Stratification Models 
Recommended in Non-ST Elevation Myocardiai 
Infarction and Unstable Angina 
Ali F. Sonel, Chester B. Good, Mary E. Kelley, Lauren Wall, Jeffrey Whittle, Michael J. 
Fine. VA Pittsburgh Healthcare System, Center for Health Equity Research and 
Promotion, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA 
Background: Non-ST elevation MI (NSTEMI) and unstable angina (UA) patients (pts) 
represent a heterogeneous population. ACC/AHA guidelines for NSTEMI and UA recom- 
mend 3 different risk stratification models (AHCPR, PURSUIT, TIMI). 
Methods: The relative accuracy of each risk model cited by the guidelines was prospec- 
tively studied in 566 pts admitted with suspicion of Ml. Information was obtained from 
chart review and clinical follow up. The end-point was 30-day death or new Ml. 
Results: Mean age was 67 +/- 12 years. The AHCPR Model, PURSUIT Model and the 
TIMI Model identified 85%. 42% and 9% of pts as “high-risk’ respectively. Using only car- 
diac marker and ECG criteria, 63% of pts were identified as high-risk. At 30 days 56 of 
566 patients (10%) had a cardiac event. Among all three model variables, hemodynamic 
instability (p<O.OOi), pulmonary edema (p<O.OOl), cardiac markers (p<O.OOl), age 
(p=O.O35), ST changes (p=O.O5), Canadian Cardiovascular Class Ill-IV (p=O.O36), not 
being on aspirin prior to admission(p=0.015) were predictive of events. 
% Event % Event Sensitivity Specificity p value 
High-Risk Not High-Risk 
AHCPR Model 1 1% 4% 95% 10% 0.031 
PURSUIT Model 14% 8% 57% 60% 0.016 
TIMI Model 10% 10% 9% 91% NS 
ECG and Markers 14% 4% 85% 39% <O.OOl 
Conclusions: Although both the AHCPR Model and the PURSUIT Model were 
predictive of events, the former was non-specific. A model based only on the ECG and 
marker criteria predicted events with good sensitivity and moderate specificity. The TIMI 
Risk score was not predictive of events. Future models for risk stratification should rely 
more on objective markers and ECG criteria and should be derived and validated 
prospectively in a non-selected population of pts. 
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851-l Effect of Ethnicity on Distrust Toward Medical 
Researchers and Willingness to Join a Cardiovascular 
Drug Prevention Trial 
Joel B. Braunstein, Steven P. Schulman, Neil R. Powe, The Johns Hopkins Medical 
Institutions, Baltimore, MD 
Background: Minority underrepresentatlon exists I” medical research including cardio- 
vascular disease (CVD) clinical trials. We asked whether African-Americans (AA) differ 
from Caucasians (C) in their distrust toward medical researchers and whether this influ- 
ences their willingness to participate (WTP) in a clinical trial. 
Methods: We approached 717 randomly selected patients from 13 Maryland-based out- 
patient cardiology and general medicine clinics between May and August 2002 to com- 
plete a self-administered survey regarding their WTP in a CVD drug prevention trial. 
Patients read a trial description that contained information similar to that in a consent 
form and reported their WTP using a B-point scale. Medical researcher distrust was 
assessed using a previously published 7-point index. We determined the relation 
between ethniclty and distrust, and how these factors influenced WTP, while adjusting for 
soclodemographlcs. 
Results: 595 patients (83% response) completed the survey: mean (SD) age = 53.6 
March 19,2003 
Conclusion: AA express much greater distrust toward medical researchers, and distrust 
IS an important negative predictor of WTP in clinical trials. Greater distrust toward medi- 
cal researchers may paltially explain AA underrepresentation in clinical trials. 
2:15 p.m. 
851-2 Ramifications of Cost-Sharing for 21,732 Patients With 
Congestive Heart Failure: Early Results From the Safety 
and Financial Ramifications of Emergency Department 
Copayments (SAFE) Study 
John Hsu Mary Price, Richard Brand, Bruce Fireman, Joseph P. Newhouse, Joseph V. -I 
Selby, Kaiser Foundation Research Institute, Oakland, CA, Harvard University, 
Cambridge. MA 
Background Millions of Americans are facing Increasing levels of cost-sharing, which 
are designed to promote more efficient resource use, but have unclear clinical conse- 
quences. We investigated the impact of cost-sharing for emergency care on Emergency 
Department (ED) visits and hospitalizations in a cohort of patients with congestive heart 
failure (CHF). Methods As part of an AHRQ-sponsored quasi-experimental study, we 
examined the effect of ED copayment levels on ED visits and hospitalizations during 
1999- 2001 in adult congestive heati failure (CHF) patients. All subjects were members 
of Kaiser Permanent+Norihem California, an integrated, managed care delivery sys- 
tem. We classified ED copayments of $20 or greater as High, and compared the esti- 
mated relative rates of monthly ED use and hospitalizations by copayment level using a 
gamma random effects model, adjusting for age, gender, medical center, a case-mix pro- 
penslty score, baseline cardiovascular medication use, and time. We used the 118 hier- 
archical condition categories (DxCG based HCC’s) to calculate the propensity score. 
Results The 21,732 subjects tended to be male (55%) and 65 years or older (74%; mean 
age 71 years, SD=i2). In 1999, 14% of subjects had High ED copayments; this percent- 
age increased to 60% I” 2000 and 70% in 2001. The number of patients with Medicare 
remained around 67% during the study period; the remainder had commercial prepaid 
Insurance. The mean ED visit and hospitalization rates were 132.2 and 57.8 visits per 
100 person-months respectively. In the multivariate models, subjects with a High ED 
copayment had a relative ED visit rate of 0.97 (95% Cl: 0.95 - 0.99), and hospitalization 
rate of 1 .O (95% Cl: 0.97 - 1 05). Conclusion In chronic disease patients, copayments 
for ED visits were associated with a small decrease in ED use, but were not associated 
with significant changes in hospitalizations. These preliminary data suggest that cost- 
sharing for emergency care could reduce resource consumption and costs without harm- 
ing patients’ health. Additional analyses will investigate changes in other clinical out- 
comes including mortality and in total costs. 
2:30 p.m. 
851-3 influence of Physician Specialty on Care and Outcomes 
of Acute Coronary Syndrome Patients: Results From 
CRUSADE 
Eric D. Peterson, Matthew T. Roe, Yun Li, Robert A. Harrington, Ralph G. Brindls, Sidney 
Smith, W. Brian Gibler, E. Magnus Ohman, Duke Clinical Research Institute, Durham, 
NC 
Background: We investigated the degree to which care of patlents with NSTE acute COT- 
onary syndrome (ACS) varies by the speciality of the primary treating physician. We also 
associated these care differences with acute patient outcomes. Methods: Using the 
CRUSADE National Registry, we examined 18,985 high risk ACS pts with + cardiac 
markers and/or ST depression treated at 289 US hospitals in 2001-02. We compared 12 
class I ACCiAHA guideline cars processes, as well as, in-hospital outcomes by the MD 
primarily responsible for in-hospital care (cardiology vs non-cardiology). Care and out- 
come results were also adjusted for patient casemix and for hospital features (academic 
status, hospital facilities, bed size and % pts treated by cardiology). Results: Overall, 
43% of ACS patients were primarily cared for by non-cardiologists. Table 1 provides 
selected care processes and outcomes by speciality and the adjusted odds ratio for 
receiving that treatment or outcome for cardiologists’ care vs not. Conciusions: Patients 
with NSTE ACS were significantly more likely to receive ACC/AHA guidelines indicated 
treatments if they were cared for by a cardiologist Patients’ acute mortality risks was also 
significantly lower with cardiologist care even after adjusting for presenting clinical factors 
and hospital features. This study demonstrates the need to more widely disseminate 
national cardiac care guidelines for NSTE ACS to all physicians. 
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Selected Care Process or 
outcome 
Aspirin ~24 hrs 
Beta-Blocker <24 hrs 
Heparin ~24 hrs 
Clopidogrel<24 hrs 
GP Ilb-llla <24 hrs 
Beta-Blocker at D/C 
ACE Inhibitor at D/C 
Lipid-Lowering Drug at DIG 
Cardiac Catheterization 
In-Hospital Mortality 
Cards 
MD 
92% 
77% 
86% 
42% 
39% 
61% 
60% 
79% 
77% 
3.3% 
Non-Cards Adjusted OR’ (95% 
MD Cf) 
86% 1.34(1.2-1.5) 
73% 1.32 (1.2-l .4) 
70% 1.69 (1.4-2.0) 
26% 1.63 (1.5-1.6) 
21% 1.95 (1.7-2.2) 
79% 1.20 (1.1-1.3) 
59% 1.10 (1.0-1.2) 
72% 1.21 (1.1-1.4) 
46% 2.53 (2.3-2.6) 
7.1% 0.75 (0.6-0.9) 
*Adjusted Odds Ratio (Cardiology care vs Non-Cardiology) controlling for 17 patient 
clinical factors and 4 Hospital features (academic status, cath/PCl facilities, bed size, 
and % pts cared for by cardiologist). 
2:45 p.m. 
851-4 Are Patients Properly Informed Prior to 
Revascularization Decisions? 
Karen P. Alexander, Tina Harding, Laura Coombs, Eric Peterson, Duke Clinical 
Research Institute, Durham, NC 
Background: Ideally, the decision for invasive cardiac care is made after pt and doctor 
weigh the risks and benefits. Informed consent and good clinical practice require discus- 
sion of these risks and benefits, but the degree to which pts comprehend this information 
is unknown. 
Methods We surveyed 679 pts admitted for chest pain prior to decision for cardiac cath 
(CC) (mean age 69.4yrs, 46% female, 65% white, 56% high school grads). Followup sur- 
vey at 6 wks, asked pts to identify and quantify risks and benefits for PCI or CABG from a 
multi-choice list. 
Results: Overall, 65% had CC, 16% had PCI. and 6% had CABG. At follow-up, 94% of 
were satisfied with their decision, 93% felt it was their decision to make, 69% felt ade- 
quately informed, and 62% felt they understood risks and benefits. Still, when choosing 
from a list, 42% of pts could not identify any risks of PCI and 41% of pts could not identify 
any benefits from PCI (Table). For CABG, 45% of pts could not identify any risks, and 
22% of pts could not identify any benefits. When asked to quantify risks (from 0.01 to 
20%). 76% of PCI pts and 57% of CABG pts did not know. Pts who knew benefits of PCI 
and CABG had higher satisfaction with their decision (p=O.O3 and 0.006 respectively). 
Conclusion: The basic tenants of informed consent are not met as assessed by pt 
recall. Half of all pts are unable to recount risks or benefits, and 75% could not quantify 
them. Further investigation into optimum methods for information transfer to pts is war- 
ranted. 
Benefits of PCI Benefits of CABG 
Prolong Life 37% 66% 
Relieve Symptoms 46% 60% 
Prevent Heart Attack 36% 57% 
Do not know 42 % 22% 
3:oo p.m. 
851-5 Economic Burden of Nonischemic Congestive Heart 
Failure: Evidence From PRAISE-2 
Padma Kaul Linda Davidson-Ray, Patricia Cowper. Lawrence Liao, Daniel Mark, Duke -I 
Clinical Research Institute, Durham. NC 
To characterize long-ten costs associated with nonischemic congestive heart failure 
(CHF). we studied 1253 US patients enrolled in the PRAISE-2 trial (inclusion critena: 
NYHA class Ill or IV CHF of non-ischemic etiology). 
Hospttal billing data were collected as part of a prospective economic sub-study. Median 
follow-up was 2.2 years, during which 615 (65%) patients were hospitalized and 55 (4%) 
underwent cardiac transplants. Non-hospitalized patients were vounaer (median aae 56 
vs. 59 years), had higher ejection fractions (24% vs. 21%) and~shorter duration o;CHF 
H .6 vs. 3.1 vearsl and were less likely to be diabetic 116% vs. 22%) or classified as 
NYHA class IV (12% vs. 24%). Total hospltallzation cost for the cohort was estimated at 
over 29 million (US $, 2000); with transplant patients accounting for just under 25% of the 
total cost (Table). Excluding transplant patients, patients in highest cost quartile 
(>$32.000) were mc~re likely to be male (72% vs. 62%), classified as NYHA class IV 
(33% “s. 21%), have CHF as a result of alcohol dependence (32% “s. 19%), and have 
longer duration of CHF (5 vs. 4 years). 
Conclusion: Our study is the first to demonstrate the tremendous economic burden of 
non-ischemic heart failure. While waiting for cardiac transplants remains the major cost 
driver, duration and severity of disease are correlated with increased resource utilization 
and underlme the need for aggressive pharmacotherapy aimed at improving LV function 
in this population. 
‘~~0.05 for withln subgroup comparison 
Subgroup 
Total 
Age<75 years 
Age>75 years 
Female 
Male 
NYHA Ill 
NYHA IV 
N Death 
% 
125 31.5 
3 
113 30.2 
0 
123 43.9 
425 24.5’ 
626 35.1 
loo 26.0 
6 
246 45.9 
Ejection fraction <= 696 35.6’ 
25% 
Ejection fraction > 355 21.1 
25% 
No Transplants 119 32.1’ 
6 
Transplants 55 16.2 
Hospitalizatio Average Length of Average total 
n % stay cost 
65.0 20 $23,676 
63.4 21’ $24,739 
60.5 15 $15,951 
66.2 16 $23,676 
63.4 21 526,161 
61.7’ 20 522,092 
76.5 21 $31,092 
67.6 21’ $27,367. 
58.0 17 514,994 
63.4’ 17’ 516,657’ 
100 66 $139,068 
3:15 p.m. 
851-6 Regional Variation in Quality of Heart Failure Care: VA 
Versus Medicare 
Paul Heidenreich, Anita Deswal, Nelda Wray, VA Palo Alto Health Care System, Palo 
Alto, CA. Houston VA, Houston, TX 
We wished to determine if patient mix and/or hospital academic affiliation and board cer- 
tification rate were associated with the quality of heart failure (HF) care in the Veterans 
Affairs (VA) Health System. 
Methods. We determined compliance with three HF guidelines (ejection fraction (EF) 
measure, ACE inhibitors if EF < 40%, and warfarin if atrial fibrillation) for 13,255 outpa- 
tients through chart review at 135 VA hospitals. VAs were grouped as low (< median 
compliance for all measures) or high performers. We determined Council of Teaching 
Hospitals (COTH) membership and board certification rate for each VA. 
Results: The mean patient age was 70 years, 57% were white, and 33% had income < 
510,000 per year. Median (interquartile range) board certification at each VA was 74% 
(63-62) and 55% were COTH hospitals. Median guideline compliance was 67 (61-91) for 
ACEi use for EFc4O%, 93 (66-96) for EF measure, and 92 (62-100) for warfarin if atrial 
fibrillation. 25 (19%) hospitals were below the median on each measure. Lack of COTH 
affiliation and a low board certification rate (but not age, race or income) were associated 
with poor guideline compliance (Figure). In multivariate analysis, only COTH affiliation 
(p<O.OOOl) and board ceriification rate (p=O.Ol) were predictive of guideline compli- 
ance@ squared=0.22). 
Conclusion: Differences in academic affiliation and board certification rates explain VA 
hospital differences in compliance with heart failure guidelines more than differences in 
patient mix. 
